Last reviewed · How we verify
besivance
At a glance
| Generic name | besivance |
|---|---|
| Also known as | besifloxacin ophthalmic suspension 0.6% |
| Sponsor | Ophthalmology Consultants, Ltd. |
| Target | DNA gyrase, Topoisomerase IV |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Approved indications
- Bacterial conjunctivitis
Common side effects
- Conjunctival redness
- Blurred vision
- Eye pain
- Eye irritation
- Eye pruritus
- Headache
Key clinical trials
- Besifloxacin in Bacterial Keratitis (NA)
- Aqueous Absorption and Pharmacokinetics of Besivance Versus VIGAMOX in Patients Undergoing Phacoemulsification (PHASE4)
- A Comparison of Prophylactic Antibacterial Efficacy of Besivance vs. VIGAMOX Prior to Cataract Surgery (PHASE4)
- Swiss PACK-CXL Multicenter Trial for the Treatment of Infectious Keratitis (PHASE3)
- Effect of Topical Besifloxacin on Ocular Surface Bacterial Microbiota Prior to Cataract Surgery (PHASE1)
- Study of Ocular Penetration of Topically Administered Fluoroquinolones (PHASE4)
- Safety and Efficacy Study of Besivance™ for Treatment of Congenital Nasolacrimal Duct Obstruction in Children (PHASE1)
- A Comparison of Three Fluoroquinolone Topical Eyedrops in the Treatment of Infectious Corneal Ulcers. (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- besivance CI brief — competitive landscape report
- besivance updates RSS · CI watch RSS
- Ophthalmology Consultants, Ltd. portfolio CI